Last Updated : November 22, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Lucentis | Ranibizumab | Macular edema, diabetic | List with clinical criteria and/or conditions | Complete | ||
Lucentis | Ranibizumab injection | Macular edema, secondary to retinal vein occlusion | List with clinical criteria and/or conditions | Complete | ||
Lucentis | Ranibizumab | Macular degeneration, age-related | List with clinical criteria and/or conditions | Complete | ||
Lucentis | Ranibizumab | Myopic choroidal neovascularisation | List with criteria/condition | Complete | ||
Lumakras | sotorasib | KRAS G12C-mutated advanced NSCLC | Do not reimburse | Complete | ||
Lutathera | Lutetium Lu 177 dotatate | Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) | Reimburse with clinical criteria and/or conditions | Complete | ||
Lutathera | lutetium oxodotreotide | Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) | Reimburse with clinical criteria and/or conditions | Complete | ||
Luxturna | voretigene neparvovec | Vision loss, inherited retinal dystrophy | Reimburse with clinical criteria and/or conditions | Complete | ||
Lynparza | Olaparib | Newly Diagnosed OC | Reimburse with clinical criteria and/or conditions | Complete | ||
Lynparza | Olaparib | metastatic castration-resistant prostate cancer (mCRPC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Lynparza | olaparib | gBRCAm, HER2-negative high-risk early breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Lynparza | olaparib | Metastatic castration-resistant prostate cancer (mCRPC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Lynparza | olaparib | Breast Cancer | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | ||
Lynparza | Olaparib | Ovarian Cancer | Do not reimburse | Complete | ||
Lynparza (Resubmission) | Olaparib | Ovarian Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Lyrica | Pregabalin | Pain, Neuropathic | Do not list | Complete | ||
Lyrica | Pregabalin | diabetic peripheral neuropathy | Do not list | Complete | ||
Macugen | Pegaptanib sodium | Macular degeneration, age-related | Do not list | Complete | ||
MAR-Trientine | Trientine Hydrochloride | Wilson's Disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Mavenclad | cladribine | Multiple Sclerosis, relapsing-remitting | Reimburse with clinical criteria and/or conditions | Complete | ||
Maviret | glecaprevir pibrentasvir | Hepatitis C, chronic | Reimburse with clinical criteria and/or conditions | Complete | ||
Maviret | glecaprevir / pibrentasvir | Hepatitis C, chronic | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | ||
Mayzent | siponimod | Secondary progressive multiple sclerosis | Reimburse with clinical criteria and/or conditions | Complete | ||
MDK-Nitisinone | nitisinone | Hereditary tyrosinemia type 1 | Reimburse with clinical criteria and/or conditions | Complete | ||
Mekinist | Trametinib | Metastatic Melanoma | Reimburse with clinical criteria and/or conditions | Complete |